Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80354177 | 8035417 | 7 | F | 20110705 | 20160818 | 20110714 | 20160824 | EXP | JP-JNJFOC-20110703403 | JANSSEN | 39.38 | YR | A | M | Y | 0.00000 | 20160824 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80354177 | 8035417 | 1 | SS | STELARA | USTEKINUMAB | 1 | Subcutaneous | Y | N | 0 | 45 | MG | SOLUTION FOR INJECTION | ||||||
| 80354177 | 8035417 | 2 | SS | STELARA | USTEKINUMAB | 1 | Subcutaneous | Y | N | 0 | 45 | MG | SOLUTION FOR INJECTION | ||||||
| 80354177 | 8035417 | 3 | SS | STELARA | USTEKINUMAB | 1 | Subcutaneous | Y | N | 0 | 45 | MG | SOLUTION FOR INJECTION | ||||||
| 80354177 | 8035417 | 4 | PS | STELARA | USTEKINUMAB | 1 | Subcutaneous | Y | N | 125261 | 45 | MG | SOLUTION FOR INJECTION | ||||||
| 80354177 | 8035417 | 5 | SS | ISONIAZID. | ISONIAZID | 1 | Oral | U | 0 | 300 | MG | UNSPECIFIED | QD | ||||||
| 80354177 | 8035417 | 6 | C | PYRIDOXAL PHOSPHATE | PYRIDOXAL PHOSPHATE | 1 | Oral | 0 | 30 | MG | QD | ||||||||
| 80354177 | 8035417 | 7 | C | BETAMETHASONE BUTYRATE PROPIONATE | BETAMETHASONE BUTYRATE PROPIONATE | 1 | Topical | 0 | 1 | ML | QD | ||||||||
| 80354177 | 8035417 | 8 | C | BETAMETHASONE DIPROPIONATE. | BETAMETHASONE DIPROPIONATE | 1 | Topical | 0 | 5 | G | OINTMENT | QD | |||||||
| 80354177 | 8035417 | 9 | C | DOVONEX | CALCIPOTRIENE | 1 | Topical | 0 | 5 | G | QD | ||||||||
| 80354177 | 8035417 | 10 | C | LOCOIDON | HYDROCORTISONE BUTYRATE | 1 | Topical | 0 | 1 | G | OINTMENT | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 80354177 | 8035417 | 1 | Psoriasis |
| 80354177 | 8035417 | 2 | Psoriasis |
| 80354177 | 8035417 | 3 | Psoriasis |
| 80354177 | 8035417 | 4 | Psoriasis |
| 80354177 | 8035417 | 5 | Prophylaxis |
| 80354177 | 8035417 | 6 | Prophylaxis |
| 80354177 | 8035417 | 7 | Psoriasis |
| 80354177 | 8035417 | 8 | Psoriasis |
| 80354177 | 8035417 | 9 | Psoriasis |
| 80354177 | 8035417 | 10 | Psoriasis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 80354177 | 8035417 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 80354177 | 8035417 | Gout | |
| 80354177 | 8035417 | Hepatic function abnormal | |
| 80354177 | 8035417 | Hyperlipidaemia | |
| 80354177 | 8035417 | Liver disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 80354177 | 8035417 | 1 | 20140307 | 20140307 | 0 | |
| 80354177 | 8035417 | 2 | 20131207 | 20131207 | 0 | |
| 80354177 | 8035417 | 3 | 20130907 | 20130907 | 0 | |
| 80354177 | 8035417 | 4 | 20110607 | 20110705 | 0 | |
| 80354177 | 8035417 | 5 | 20110426 | 20110705 | 0 | |
| 80354177 | 8035417 | 6 | 20110705 | 0 | ||
| 80354177 | 8035417 | 7 | 20100330 | 0 | ||
| 80354177 | 8035417 | 8 | 20100330 | 0 | ||
| 80354177 | 8035417 | 9 | 20100330 | 0 | ||
| 80354177 | 8035417 | 10 | 20100330 | 0 |